APP Pharmaceuticals in patent dispute over branded chemotherapy drug

Related Content

No related items were found.

INDIANAPOLIS A maker of generic injectable drugs is involved in a patent infringement suit over a chemotherapy drug developed by Eli Lilly and Co., according to court documents.

Schaumburg, Ill.-based APP Pharmaceuticals submitted a new drug application for generic version of Gemzar, a treatment for non-small lung, breast, pancreatic and ovarian cancers. Lilly said the launch of APP Pharma's version of the drug would violate the patent of the drug, which expires May 7, 2013.

The complaint was filed by Lilly on Dec. 16.

© 2014 Drug Store News. All Rights Reserved.